BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han

Journal of Investigative Dermatology

Volumn 131, Issue 5, 2011, Pages 1129-1138

  Qi, Rui Qun ^a   He, Li ^b   Zheng, Song ^a   Hong, Yuxiao ^a   Ma, Lei ^a   Zhang, Shifa ^c   Zhao, Liping ^c   Guo, Xinjian ^d   Wang, Yong ^d   Yu, Jiang Yun ^b   Fu, Lan ^b   Zhang, Wei ^b   Long, Tingfeng ^b   Zhang, Chao ^a   Chen, Guohong ^a   Lin, Junping ^a   Wang, Chengliang ^e   Zhou, Li ^f   Mi, Qingsheng ^f   Weiland, Matthew ^f   Chen, John Z S ^g   McHenga, S S Salum ^h   Wang, Ya Kun ^a   McHepange, Uwesu ⁱ   Wang, Zhimin ^a   Chen, Hong Duo ^a   Gao, Xing Hua ^a   more..

^a CHINA MEDICAL UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^d QINGHAI UNIVERSITY   (China)

^e Kangle Hospital   (China)

^f Immunology Program   (United States)

^g Sheftel Associates Dermatology   (United States)

^h Pathology Laboratory   (Tanzania)

ⁱ MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROMUTAGEN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CAUCASIAN; CELL PROLIFERATION; CHINESE; CONTROLLED STUDY; DISEASE DURATION; ELASTOSIS; EXON; FEMALE; GENDER; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MELANOCYTIC NEVUS; MELANOMA; MICRODISSECTION; ONSET AGE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RADIATION EXPOSURE; SKIN BIOPSY; SKIN CANCER; SOMATIC MUTATION; SUN EXPOSURE; ULTRAVIOLET RADIATION;

EID: 79954703723     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.405     Document Type: Article

References (33)

1. Akslen LA, Puntervoll H, Bachmann IM et al. (2008) Mutation analysis ofthe EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18:29-35 (Pubitemid 351628053)
2. Bauer J, Curtin JA, Pinkel D et al. (2007) Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 127:179-82 (Pubitemid 46005676)
3. Besaratinia A, Pfeifer GP (2008) Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum Mutat 29:983-91
4. Cohen Y, Rosenbaum E, Begum S et al. (2004) Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 10:3444-7 (Pubitemid 38685451)
5. Dankort D, Curley DP, Cartlidge RA et al. (2009) Braf (V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet41:544-52
6. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54 (Pubitemid 34716871)
7. Demenais F, Mohamdi H, Chaudru V et al. (2010) Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst 102:1568-83
8. Dessars B, De Raeve LE, Morandini R et al. (2009) Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol 129:139-47
9. Dworkin AM, Ridd K, Bautista D et al. (2010) Germline variation controls the architecture of somatic alterations in tumors. PLoS Genet 6: e1001136
10. Fecher LA, Amaravadi RK, Flaherty KT (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20:183-9 (Pubitemid 351317406)
11. Friedman RJ, Rigel DS, Kopf AW (1985) Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 35:130-51 (Pubitemid 15041543)
12. Gong ZQ, Zhang L, Wang J (1992) The comprehensive survey to the ultra-violet ray on plain, sea coast and plateau in our country. J Clin Dermatol 21:70-72
13. Green A, Swerdlow AJ (1989) Epidemiology of melanocytic nevi. Epidemiol Rev 11:204-21
14. Hoeflich KP, Herter S, Tien J et al. (2009) Antitumor efficacy ofthe novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 69:3042-51
15. James MR, Dumeni T, Stark MS et al. (2006) Rapid screening of 4000 indi-viduals for germ-line variations in the BRAF gene. Clin Chem 52:1675-8 (Pubitemid 44330700)
16. Kumar R, Angelini S, Snellman E et al. (2004) BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 122:342-8 (Pubitemid 38281054)
17. Landi MT, Bauer J, Pfeiffer RM et al. (2006) MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313:521-2 (Pubitemid 44148456)
18. Lang J, MacKie RM (2005) Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 125:575-9
19. Laud K, Kannengiesser C, Avril MF et al. (2003) BRAF as a melanoma susceptibility candidate gene? Cancer Res 63:3061-5 (Pubitemid 36735852)
20. Liu W, Kelly JW, Trivett M et al. (2007) Distinct clinical and pathological features are associated with the BRAF (T1799A (V600E)) mutation in primary melanoma. J Invest Dermatol 127:900-5 (Pubitemid 46434654)
21. Maldonado JL, Fridlyand J, Patel H et al. (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878-90
22. Papp T, Schipper H, Kumar K et al. (2005) Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res 15:401-7 (Pubitemid 41558950)
23. Patton EE, Widlund HR, Kutok JL et al. (2005) BRAF mutationsare sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15:249-54 (Pubitemid 40205706)
24. Pollock PM, Harper UL, Hansen KS et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet33:19-20 (Pubitemid 36068675)
25. Poynter JN, Elder JT, Fullen DR et al. (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267-73 (Pubitemid 44090170)
26. Saldanha G, Potter L, Daforno P et al. (2006) Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 12:4499-505 (Pubitemid 44297798)
27. Sasaki Y, Niu C, Makino R et al. (2004) BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 123:177-83 (Pubitemid 38833479)
28. Shinozaki M, Fujimoto A, Morton DL et al. (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10:1753-7 (Pubitemid 38435567)
29. Sun D, Gao T, Li C (2003) Acral malignant melanoma: clinical-pathological features of 100 cases. Chinese J Dermatol 36:556-8
30. Takata M, Saida T (2006) Genetic alterations in melanocytic tumors. J Dermatol Sci 43:1-10 (Pubitemid 43817500)
31. Thomas NE, Edmiston SN, Alexander A et al. (2007) Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 16:991-7 (Pubitemid 46910102)
32. Wu J, Rosenbaum E, Begum S et al. (2007) Distribution of BRAF T1799A (V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol 29:534-7 (Pubitemid 350158863)
33. Yu H, McDaid R, Lee J et al. (2009) The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol 174:2367-77